Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Inclusion Criteria

• •Male or female patients 18-75
• •Patients with malignant solid tumors that have been diagnosed by pathology and/or cytology
• •Patients who have progressed on or who cannot tolerate available therapies or for whom curative therapy does not exist
• •Patients with at least one non-injected measurable tumor lesion per RECIST v1.1
• •Patients with lesions suitable for intratumoral injection (the lesion length is at least 10mm and not exceeding 80mm)
• •Patients enrolled in the Skin/subcutaneous lesions and deep （visceral） lesions stages of Phase Ia must agree to provide pre- and post-treatment tumor biopsy tissues
• •Patients must have adequate organ and marrow functions
• •Patients must be ≥ 4 weeks beyond treatment with any chemotherapy (6 weeks for nitrosoureas or mitomycin C), hormonal, biological, targeted agents, other investigational therapy or radiotherapy